All In Biotech

Drug Trial Radar · NCT05094050

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/Foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients

Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 18, 2022

Primary completion

Mar 17, 2023

Study completion Mar 17, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's disease (PD) is a neurological condition, which means it affects the brain. This study will evaluate how ABBV-951 is absorbed under the skin of participants with PD when administered to arm, thigh and flank compared to the abdomen. ABBV-951 is an investigational drug being developed for the treatment of PD. Study doctors randomly assign participants to 1 of 4 groups, called treatment arms. Each treatment arm receives ABBV-951 administered in a different order in the arm, high, flank and abdomen. Approximately 12 adult participants over 30 years with a diagnosis of PD will be enrolled in approximately 10 sites in the United States. Participants will receive continuous (24hours/day) subcutaneous infusion of ABBV-951 for 2 consecutive days for each infusion site (arm, thigh, flank and abdomen), for a total duration of treatment up to 12 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will be confined at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Adverse events will be monitored throughout the study.

Conditions

  • Parkinson's Disease

Interventions

  • ABBV-951Drug

    Continuous Subcutaneous Infusion (CSCI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of Levodopa (LD)Time frame: Up to 8 Days
  2. Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of LDTime frame: Up to 8 Days
  3. Minimum Observed Plasma Concentration (Cmin) of LDTime frame: Up to 8 Days
  4. Degree of Fluctuation (DFL) of LDTime frame: Up to 8 Days
  5. Swing of LDTime frame: Up to 8 Days
  6. Maximum Observed Plasma Concentration (Cmax) of Carbidopa (CD)Time frame: Up to 8 Days
  7. Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of CDTime frame: Up to 8 Days
  8. Minimum Observed Plasma Concentration (Cmin) of CDTime frame: Up to 8 Days
  9. Degree of Fluctuation (DFL) of CDTime frame: Up to 8 Days
  10. Swing of CDTime frame: Up to 8 Days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Hospital /ID# 229974

    Aurora, Colorado

  • Georgetown University Hospital /ID# 230224

    Washington D.C., District of Columbia

  • Rush University Medical Center /ID# 229983

    Chicago, Illinois

  • Carolina Phase 1, LLC /ID# 239836

    Raleigh, North Carolina

  • The Movement Disorder Clinic of Oklahoma /ID# 238610

    Tulsa, Oklahoma

  • Vanderbilt University Medical Center /ID# 230255

    Nashville, Tennessee

  • Parkinson Disease Movement Disorders Clinic /ID# 245791

    Austin, Texas

  • Texas Movement Disorder Specialists /ID# 238607

    Georgetown, Texas

  • Baylor College of Medicine - Baylor Medical Center /ID# 239631

    Houston, Texas

  • University of Utah Health Care /ID# 241219

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.